ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow

Summary

Cardiovascular diseases (CVD) are currently the leading cause of death in industrialized countries and are expected to become the leading cause of death in emerging countries by 20201. According to the official Russian statistics, in 2015, CVD was the cause in 34% of deaths in Russia2.

Acute Coronary Syndrome (ACS) is the most prevalent manifestation of CVD and is associated with high mortality and morbidity. No other life-threatening disease is as prevalent or expensive to society3. In 2014 in Russian Federation 46 250 people died from acute myocardial infarction (MI) and 17 605 people died from recurrent MI4.

ACS is a clinical syndrome characterized by unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). The most common cause of ACS is reduced myocardial perfusion that results from coronary artery narrowing caused by the formation of partially or totally occlusive thrombi in response to rupture of atherosclerotic plaques on the vessel wall5-7.

In Russian Federation ACS management after ACS is provided in out-patient settings by doctors of different specialties (cardiologists and general practitioners (GPs)). However, the management of ACS in out-patient settings in some regions in Russian Federation is frequently suboptimal. Moscow city significantly differs from other parts of Russia from ACS management at hospital stage (up to 90% of PCI managed ST elevation myocardial infarction (MI) patients, no thrombolysis, short first medical contact to balloon time etc.) but it is unclear if management of post MI patients in Moscow out-patient settings is also optimal. In-hospital mortality in MI patients decreased last years but there is no data on clinical outcomes during 12 months after MI in Moscow.

This study will provide the epidemiological data about rates of major adverse cardiovascular and cerebrovascular events (MACCE) (MI, stroke, cardiovascular death) within 12 months after MI in real clinical practice in Moscow and describe DAPT at out-patient setting. The information received in this study will help to optimize management of Russian patients with ACS. The data will be used in discussion with payers

Conditions

• Heart Attack
• Stroke
• Cardiovascular Death

Sponsors & Collaborators

• AstraZeneca

  lead INDUSTRY

Principal Investigators

• Olga Pesheva · GBUZ GP # 121 DZM

• Tatyana Yurchak · GBUZ GP # 52 DZM

• Veronika Vovk · GBUZ GP # 2 DZM

• Dmitriy Privalov · GBUZ GKB # 51 DZM

• Maria Klepikova · GBUZ GKB # 13 DZM

• Olga Belkorey · GBUZ GP # 218 DZM

• Natalya Karabinskaya · GBUZ GP # 19 DZM

• Natalya Bosyakova · GBUZ GP # 19 DZM

• Marina Lepatova · GBUZ GP # 107 DZM

• Elena Dorofeeva · FGBU "Polyclinic # 1" Administrative Department of the President of the Russian Federation

• Irina Shoshina · GBUZ GP # 109 DZM

• Darya Semenova · GBUZ GP # 23 DZM

• Elena Zherebetskaya · GBUZ KDC # 2 DZM

• Marina Yarygina · GBUZ GP # 175 DZM

• Elena Lukinskaya · GBUZ GP # 115 DZM

• Irina Borovikova · GBUZ GP # 209 DZM

• Tatiana Sladkova · GBUZ GP # 22 DZM

• Elena Demyanova · GBUZ GP # 64 DZM

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-03-25

Primary Completion

2021-10-19

Completion

2021-10-19

Countries

• Russia

Study Locations